{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:55:11Z","timestamp":1793314511682,"version":"4.5.0"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,8]]},"DOI":"10.1097\/ico.0b013e318064584a","type":"journal-article","created":{"date-parts":[[2007,7,24]],"date-time":"2007-07-24T08:03:13Z","timestamp":1185264193000},"page":"858-860","source":"Crossref","is-referenced-by-count":48,"title":["Acquired Trichomegaly and Symptomatic External Ocular Changes in Patients Receiving Epidermal Growth Factor Receptor Inhibitors"],"prefix":"10.1097","volume":"26","author":[{"given":"Grace","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surendra","family":"Basti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee M","family":"Jampol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-16-20210204","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1093\/annonc\/mdh257","article-title":"Pharmacological background of EGFR targeting.","volume":"15","author":"Castillo","year":"2004","journal-title":"Ann Oncol"},{"key":"R2-16-20210204","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1067\/mcn.2002.125874","article-title":"The epidermal growth factor receptor: a new target for anticancer therapy.","volume":"26","author":"Grunwald","year":"2002","journal-title":"Curr Probl Cancer"},{"key":"R3-16-20210204","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1200\/JCO.2002.10.112","article-title":"ZD1839, a selective oral epidermal growth factor receptor-tyrosin kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a Phase I trial.","volume":"20","author":"Ranson","year":"2002","journal-title":"J Clin Oncol"},{"key":"R4-16-20210204","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/annonc\/mdi279","article-title":"Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors.","volume":"16","author":"Segaert","year":"2005","journal-title":"Ann Oncol"},{"key":"R5-16-20210204","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1080\/02841860310006038","article-title":"Epidermal growth factor receptor inhibition induces trichomegaly.","volume":"42","author":"Dueland","year":"2003","journal-title":"Acta Oncol"},{"key":"R6-16-20210204","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/j.1365-2133.2004.06265.x","article-title":"Trichomegaly following treatment with gefitinib (ZD1839).","volume":"151","author":"Pascual","year":"2004","journal-title":"Br J Dermatol"},{"key":"R7-16-20210204","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/1523-1747.ep12874601","article-title":"Immunolocalization of epidermal growth factor receptors in normal developing human skin.","volume":"94","author":"Nanney","year":"1990","journal-title":"J Invest Dermatol"},{"key":"R8-16-20210204","first-page":"1959","article-title":"Genetically null mice reveal a central role for epidermal growth factor receptor in the differentiation of the hair follicle and normal hair development.","volume":"150","author":"Hansen","year":"1997","journal-title":"Am J Pathol"},{"key":"R9-16-20210204","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1006\/exer.1994.1152","article-title":"Effect of epidermal growth factor, hepatocyte growth factor, keratinocyte growth factor on proliferation, motility and differentiation of human corneal epithelial cells.","volume":"59","author":"Wilson","year":"1994","journal-title":"Exp Eye Res"},{"key":"R10-16-20210204","first-page":"725","article-title":"Ocular findings in patients with solid tumors treated with the epidermal growth factor inhibitor tyrosine kinase inhibitor geftinib (Iressa ZD 1839) in phase I and II clinical trials.","volume":"19","author":"Turro","year":"2005","journal-title":"Eye"},{"key":"R11-16-20210204","first-page":"3639","article-title":"Distribution and function of EGFRI in human tissue and the effect of EGFR tyrosine kinase inhibition.","volume":"23","author":"Yano","year":"2003","journal-title":"Anticancer Res"}],"container-title":["Cornea"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ICO.0b013e318064584a","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T19:27:52Z","timestamp":1621884472000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003226-200708000-00016"}},"subtitle":["Case Reports and a Review of Literature"],"short-title":[],"issued":{"date-parts":[[2007,8]]},"references-count":11,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/ico.0b013e318064584a","relation":{},"ISSN":["0277-3740"],"issn-type":[{"value":"0277-3740","type":"print"}],"subject":[],"published":{"date-parts":[[2007,8]]}}}